Efficacy and Safety Study of Lomustine/Temozolomide Combination Therapy vs. Standard Therapy for Glioblastoma Patients

NCT01149109 | Completed Phase 3 DMC

• 2 other identifiers: CeTeG2009-011252-22
• Study Type: interventional
• Target: 141
• Locations: 1 country
• Sites: 12

Brief Summary

The prognosis of patients with newly diagnosed glioblastoma is dismal despite recent therapeutic improvements Using standard therapy with temozolomide (TMZ) and radiotherapy (60 Gy), the median overall survival time (mOS) is 14.6 months (Stupp et al., 2005). Since in a previous non-randomized bicentric phase II trial, primary combination chemotherapy with lomustine (CCNU) and TMZ was highly effective (mOS 23 months; UKT-03 trial; Herrlinger et al., 2006; Glas et al., 2009) the proposed trial further investigates the efficacy of CCNU/TMZ in a randomized multicenter phase III setting against standard therapy. In case the projected phase III trial confirms the phase II data, CCNU/TMZ combination would be significantly better than TMZ monotherapy and would thus be the new standard treatment for newly diagnosed GBM patients with a methylated MGMT promotor. Thus, this trial has the potential to profoundly change the standard therapy of this most aggressive brain tumor. Since in the previous trial only patients with a methylated MGMT (mMGMT) promoter had a benefit from CCNU/TMZ (mOS in the mMGMT group 34 months, in the non-mMGMT group 12.5 months; Glas et al., 2009) while patients with a non-methylated MGMT did not have any benefit, the trial is restricted to mMGMT patients.The CeTeG trial randomizes in a 1:1 fashion newly diagnosed GBM patients (18-70 years) for either standard TMZ therapy (concomitant and 6 courses à 4 weeks of adjuvant TMZ therapy) or experimental CCNU/TMZ therapy (6 courses à 6 weeks). Both arms include standard radiotherapy (RT) of the tumor site (30 x 2 Gy). Assuming that CCNU/TMZ therapy increases the median overall survival (mOS) from 48.9% (standard TMZ) to 70% (CCNU/TMZ; 75% in the previous phase II trial, Glas et al., 2009), 2 x 68 patients have to be accrued. Patients will be accrued over 24 months and each patient will be followed for at least 24 months adding up to a total minimal duration of the time from first patient in until the end of the follow-up time of 48 months. The primary endpoint is overall survival; secondary endpoints include progression-free survival, response rate, acute and late toxicity, and quality of life.

Conditions

Glioblastoma

Keywords

MGMT promotor status; overall survival

Outcome Measures

Primary Outcomes (1)

• overall survival

  after follow up (4 years)

Secondary Outcomes (6)

• progression free survival

  after follow up (4 years)

• best response rate determined by MRI

  after follow up (4 years)

• frequency of delay of the next Lomustine/Temozolomide or Temozolomide course

  during treatment period (2 years)

• acute toxicity during radiotherapy and chemotherapy according to CTC AE V3.0

  during treatment period (2 years)

• quality of life

  including follow up (4 years)

Study Arms (2)

lomustine (CCNU) + temozolomide (TMZ) and radiotherapy

EXPERIMENTAL

60 Gy standard radiotherapy (RT, 30 x 2 Gy) Six 42-day courses of oral CCNU 100 mg/m2 (day 1) and oral TMZ 100 mg/m2 (day 2-6), first CCNU application during the first week of RT CCNU/TMZ and radiotherapy start 2-5 weeks after diagnosis (day of surgery for glioblastoma (GBM)). In courses 2-6, TMZ dose are adjusted according to the hematotoxicity observed in the previous course and can be increased stepwise up to 200 mg/m2/day

Drug: Temozolomide and lomustine

temozolomide and radiotherapy

ACTIVE COMPARATOR

60 Gy standard radiotherapy (RT, 30 x 2 Gy) and concomitant TMZ therapy (daily TMZ 75 mg/m2) starting with the first day of radiotherapy Six 28-day courses of TMZ (day 1-5) starting 4 weeks after completion of radiotherapy. In the first course TMZ is given at a dose of 150 mg/m2/day, in case no toxicity is observed, the 2nd course is applied at a daily dose of 200 mg/m2

Drug: Temozolomide

Interventions

Temozolomide and lomustine DRUG

Also known as: Temodal, Temomedac, CeCeNu

lomustine (CCNU) + temozolomide (TMZ) and radiotherapy

Temozolomide DRUG

Also known as: Temodal, Temomedac

temozolomide and radiotherapy

Eligibility Criteria

• Age: 18 Years - 70 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• written informed consent
• patients have to be in a cognitive state that allows them to understand the rationale and necessity of study therapy and procedures.
• newly diagnosed histologically proven GBM or gliosarcoma WHO Grad IV
• methylated MGMT promoter in the tumor
• estimated life expectancy of at least 12 weeks
• Karnofsky Performance Score (KPS) ≥ 70%
• patient compliance and geographic proximity that allow adequate follow up
• male and female patients with reproductive potential must use an approved contraceptive method
• pre-menopausal female patients with childbearing potential: a negative serum pregnancy test must be obtained prior to treatment start
• Adequate organ function as described below:
• Adequate bone marrow reserve:
• white blood cell (WBC) count \> 3000/µl, granulocyte count \>1500/µl, platelets \> 100000/µl, haemoglobin ≥ 10 g/dl Adequate liver function bilirubin \< 1.5 times above upper limit of normal range (ULN), ALT and AST \< 3 times ULN creatinine \< 1.5 times ULN
• Adequate blood clotting:
• PT and PTT within normal limits Negative HIV test

You may not qualify if:

• prior malignancy
• prior chemotherapy
• prior radiotherapy to the brain
• concurrent administration of any other anti-tumor therapy
• allergy or other intolerability of temozolomide, CCNU, dacarbazine or other nitrosourea derivatives
• unable to undergo MRI
• past medical history of diseases with poor prognosis
• known HIV infection, active Hepatitis B or C infection
• any active infection
• female patients that are pregnant or breastfeeding
• patients with reproductive potential who do not accept to use contraception
• treatment in another clinical trial
• any psychological, cognitive, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up scheduled visits (at the discretion of investigator)

Sponsors & Collaborators

• University Hospital, Bonn: lead

Study Sites (12)

Depatment of Neurosurgery, Charité, University Hospital Berlin

Berlin, 13353, Germany

Location

Department of Neurology, University Hospital Bochum

Bochum, 44892, Germany

Location

Department of Neurology, University Hospital Bonn

Bonn, 53105, Germany

Location

Department of Neurosurgery, University Hospital Cologne

Cologne, 50937, Germany

Location

Department of Neurosurgery, University Hospital Dresden

Dresden, 01307, Germany

Location

Department of Neurosurgery, University Hospital Duesseldorf

Düsseldorf, 40225, Germany

Location

Department of Neurosurgery, University Hospital Frankfurt

Frankfurt, 60528, Germany

Location

Department of Radiooncology, University Hospital Leipzig

Leipzig, 04103, Germany

Location

Department of Neurosurgery, University of Heidelberg, Medical Faculty of Mannheim

Mannheim, 68167, Germany

Location

Department of Neurosurgery, University Hospital Munich (LMU)

Munich, 81377, Germany

Location

Department of Neurosurgery, University Hospital Muenster

Münster, 48149, Germany

Location

Department of Neurology, University Hospital Regensburg

Regensburg, 93053, Germany

Location

Related Publications (4)

• Weller J, Schafer N, Schaub C, Tzaridis T, Zeyen T, Schneider M, Potthoff AL, Giordano FA, Steinbach JP, Zeiner PS, Kowalski T, Sabel M, Hau P, Krex D, Grauer O, Goldbrunner R, Schnell O, Tabatabai G, Ringel F, Schmidt-Graf F, Brehmer S, Tonn JC, Bullinger L, Vajkoczy P, Glas M, Vatter H, Herrlinger U, Seidel C. Patterns, predictors and prognostic relevance of high-grade hematotoxicity after temozolomide or temozolomide-lomustine in the CeTeG/NOA-09 trial. J Neurooncol. 2023 Jan;161(1):147-153. doi: 10.1007/s11060-022-04203-4. Epub 2023 Jan 7.

  PMID: 36609807 DERIVED

• Tzaridis T, Schafer N, Weller J, Steinbach JP, Schlegel U, Seidel S, Sabel M, Hau P, Seidel C, Krex D, Goldbrunner R, Tonn JC, Grauer O, Kebir S, Schneider M, Schaub C, Vatter H, Coch C, Glas M, Fimmers R, Pietsch T, Reifenberger G, Herrlinger U, Felsberg J. MGMT promoter methylation analysis for allocating combined CCNU/TMZ chemotherapy: Lessons learned from the CeTeG/NOA-09 trial. Int J Cancer. 2021 Apr 1;148(7):1695-1707. doi: 10.1002/ijc.33363. Epub 2020 Nov 10.

  PMID: 33113214 DERIVED

• Weller J, Tzaridis T, Mack F, Steinbach JP, Schlegel U, Hau P, Krex D, Grauer O, Goldbrunner R, Bahr O, Uhl M, Seidel C, Tabatabai G, Brehmer S, Bullinger L, Galldiks N, Schaub C, Kebir S, Stummer W, Simon M, Fimmers R, Coch C, Glas M, Herrlinger U, Schafer N. Health-related quality of life and neurocognitive functioning with lomustine-temozolomide versus temozolomide in patients with newly diagnosed, MGMT-methylated glioblastoma (CeTeG/NOA-09): a randomised, multicentre, open-label, phase 3 trial. Lancet Oncol. 2019 Oct;20(10):1444-1453. doi: 10.1016/S1470-2045(19)30502-9. Epub 2019 Sep 2.

  PMID: 31488360 DERIVED

• Herrlinger U, Tzaridis T, Mack F, Steinbach JP, Schlegel U, Sabel M, Hau P, Kortmann RD, Krex D, Grauer O, Goldbrunner R, Schnell O, Bahr O, Uhl M, Seidel C, Tabatabai G, Kowalski T, Ringel F, Schmidt-Graf F, Suchorska B, Brehmer S, Weyerbrock A, Renovanz M, Bullinger L, Galldiks N, Vajkoczy P, Misch M, Vatter H, Stuplich M, Schafer N, Kebir S, Weller J, Schaub C, Stummer W, Tonn JC, Simon M, Keil VC, Nelles M, Urbach H, Coenen M, Wick W, Weller M, Fimmers R, Schmid M, Hattingen E, Pietsch T, Coch C, Glas M; Neurooncology Working Group of the German Cancer Society. Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA-09): a randomised, open-label, phase 3 trial. Lancet. 2019 Feb 16;393(10172):678-688. doi: 10.1016/S0140-6736(18)31791-4. Epub 2019 Feb 14.

  PMID: 30782343 DERIVED

Related Links

• Clinical Neuro-Oncology, University of Bonn

MeSH Terms

Conditions

Glioblastoma

Interventions

Temozolomide; Lomustine

Condition Hierarchy (Ancestors)

Astrocytoma; Glioma; Neoplasms, Neuroepithelial; Neuroectodermal Tumors; Neoplasms, Germ Cell and Embryonal; Neoplasms by Histologic Type; Neoplasms; Neoplasms, Glandular and Epithelial; Neoplasms, Nerve Tissue

Intervention Hierarchy (Ancestors)

Dacarbazine; Triazenes; Organic Chemicals; Imidazoles; Azoles; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds; Nitrosourea Compounds; Urea; Amides; Nitroso Compounds

Study Officials

• Ulrich Herrlinger, Prof. Dr.

  Division of Neurooncology, Departement of Neurology, University Hospital Bonn

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: phase 3
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Head, Division of Clinical Neurooncology

Study Record Dates

• First Submitted: June 14, 2010
• First Posted: June 23, 2010
• Study Start: October 1, 2010
• Primary Completion: April 6, 2017
• Study Completion: April 6, 2017
• Last Updated: June 14, 2017

Record last verified: 2017-06

Locations

DE (12)